APA (7th ed.) Citation

Ständer, S., Pinter, A., Hougeir, F. G., Guyot, P., Xu, Y., Praestgaard, A. H., . . . Bastian, M. (2025). Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison. Dermatology & Therapy, 15(9), 2537. https://doi.org/10.1007/s13555-025-01479-y

Chicago Style (17th ed.) Citation

Ständer, Sonja, et al. "Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison." Dermatology & Therapy 15, no. 9 (2025): 2537. https://doi.org/10.1007/s13555-025-01479-y.

MLA (9th ed.) Citation

Ständer, Sonja, et al. "Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison." Dermatology & Therapy, vol. 15, no. 9, 2025, p. 2537, https://doi.org/10.1007/s13555-025-01479-y.